Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Prescient Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Prescient has some very positive findings to share about its OmniCAR platform’s tumour-killing abilities
Health & Biotech
ASX Health Wrap: Resonance gains ground, with sights set on FDA approval for LiverSmart
Health & Biotech
CAR-T therapy is potentially a $20bn market. Here’s how it works and the ASX players in the space
Health & Biotech
Health Kick: Prescient Therapeutics’ YTD share price soars +220% after progress in clinical studies and CAR-T platform
Health & Biotech
Prescient announces key hire as leading US neurosurgeon Donald M O’Rourke joins its Advisory Board
Stockhead TV
90 Seconds With… Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)
Health & Biotech
Prescient Therapeutics finished the June quarter stronger than ever
Health & Biotech
‘Very encouraging’: Two cancer patients see partial remission and long-lasting benefits after treatment with Prescient’s PTX-100
Health & Biotech
Prescient shares rip higher as immunogenicity testing results for OmniCAR ‘could not have been better’
News
Market Highlights and 5 ASX Small Caps to watch on Monday
Health & Biotech
Safety in mind as Prescient Therapeutics develops next-generation CAR-T platform
Health & Biotech
ScoPo’s Powerplays: Buying opportunities in a volatile week
Health & Biotech
Prescient equips CAR-T cells with cancer-fighting binders in manufacturing milestone
Health & Biotech
ScoPo’s Powerplays: The immune oncology space finally gets long overdue attention
Health & Biotech
Invion led a group of ASX cancer stocks up after promising news
Health & Biotech
Budget review: Here’s what ASX biotech players thought of the ‘patent box’
Health & Biotech
